Precision Health

Neurology, Cardiology, and Chronic Disease in the AI Era

“The tools exist. The integration does not.”

While oncology has been the primary proving ground for personalised medicine, other major disease areas remain under-served. Neurology, cardiology, and chronic diseases such as diabetes and obesity could benefit substantially from AI-driven tools, biomarker stratification, and digital diagnostics. Yet these opportunities remain largely unrealised due to systemic fragmentation, siloed reimbursement, and insufficient cross-sector coordination.

This session will feature thematic spotlights on key use cases:

• In cardiology, the integration of AI for echocardiogram interpretation, biomarker-guided therapeutic pathways, and pan-European procurement of diagnostic platforms.
• In neurology, early detection of Alzheimer’s and Parkinson’s using voice biomarkers and multimodal AI models, as well as the role of wearable devices in tracking disease progression.
• In obesity and chronic disease management, the role of microbiome-targeted interventions, digital adherence tools, and personalised prevention models.
• In multimorbidity, the convergence of cardiometabolic and cancer data to develop predictive analytics and integrated care pathways.

We will also examine policy levers to scale these innovations, including data interoperability through the European Health Data Space, regulatory sandboxes for AI validation, and EAPM-led recommendations on cross-disease digital health policy alignment.

Conclusion:

Personalised medicine must extend beyond oncology. To realise the potential of precision health, Europe must adopt an integrated, cross-disease strategy that combines AI, digital diagnostics, and equitable access policies.